Incidence of cardiac events slightly higher with trastuzumab
the ONA take:
The cumulative incidence of cardiac events (CE) at 6 years was slightly higher in patients with HER2-positive early breast cancer receiving trastuzumab, a new study published online ahead of print in the Journal of Clinical Oncology has shown.
For the study, patients received adjuvant doxorubicin plus cyclophosphamide followed by either weekly paclitaxel (arm A), paclitaxel then trastuzumab (arm B), or paclitaxel plus trastuzumab followed by trastuzumab alone (arm C).
Results showed that the cumulative incidence of cardiac events was 0.6% in arm A, 2.8% in arm B, and 3.4% in arm C.
Researchers found that left ventricular ejection fraction (LVEF) recovered in the majority of patients that developed congestive heart failure.
The study also demonstrated that age 60 years or older, LVEF <65% at baseline, and use of antihypertensive medications were associated with an increased risk of cardiac events in patients receiving trastuzumab.
“The cumulative incidence of CE at 6 years was slightly higher with the addition of trastuzumab; however, the late development of CE is infrequent,” the authors conclude. “Trastuzumab (in the context of anthracycline- and taxane-based therapy) continues to have a favorable benefit-risk ratio.”
The cumulative incidence of cardiac events (CE) at 6 years was slightly higher in patients with HER2-positive early breast cancer receiving trastuzumab.
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Risk of Second Cancers Increased in Hodgkin Lymphoma Survivors
- Directly Informing Patients of Breast Cancer Risk, Options Improves Follow-Up Screening
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Free Lung Cancer Screening Findings Support Continual Screenings in High-Risk Populations
- Parental Self-persuasion in Low-Income Groups Improves HPV Vaccination Rates
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Shared Decision-making Visits Improved Comfort With Lung Cancer Screening Decisions
- Temozolomide With Radiotherapy for Glioblastoma Provides Some Survival Benefit in Elderly
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|